A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...

Lung cancer among nonsmokers is associated with germline risk factors, and EGFR/ALK-targeted therapies provide substantial ...

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, ...

REDMOND, Wash., May 23, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab brengitecan (iza-bren), a ...

We are gratified the FDA has granted Orphan Drug Designation to daraxonrasib for the treatment of pancreatic cancer, a devastating disease with limited therapeutic options and representing a large ...

Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa These findings ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...